{
    "2018-01-30": [
        [
            {
                "time": "2018-01-31",
                "original_text": "Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX",
                "features": {
                    "keywords": [
                        "Drug/Biotech",
                        "Q4",
                        "Earnings",
                        "LLY",
                        "VRTX"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-31",
                "original_text": "Eli Lilly’s 4Q17 Estimates: Human Pharmaceuticals Business",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "4Q17",
                        "Estimates",
                        "Human Pharmaceuticals"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-31",
                "original_text": "Pre-Market Earnings Report for January 31, 2018: BA, LLY, TMO, ANTM, EPD, ADP, SPG, JCI, SIRI, IR, ERIC, WEC",
                "features": {
                    "keywords": [
                        "Pre-Market",
                        "Earnings",
                        "BA",
                        "LLY",
                        "TMO",
                        "ANTM",
                        "EPD",
                        "ADP",
                        "SPG",
                        "JCI",
                        "SIRI",
                        "IR",
                        "ERIC",
                        "WEC"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "diverse"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-31",
                "original_text": "Eli Lilly’s 4Q17 Estimates: Revenue Growth Expected",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "4Q17",
                        "Revenue Growth",
                        "Expected"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-31",
                "original_text": "Analysts’ Estimates for Eli Lilly’s 4Q17 Earnings",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Estimates",
                        "Eli Lilly",
                        "4Q17",
                        "Earnings"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}